OSLO, NORWAY-- - Bionor Pharma ASA News SummaryPlacebo-controlled, double-blind clinical study combining Vacc-4x with Celgene's Revlimid® approved to start at four clinics in Germany Study seeks ...

Successfully results from clinical study with Vacc-4x and Endocine Oslo 10.05.2012 - Successful Immunization and Safety Documented in Nasal Administration Study of the HIV Vaccine Vacc-4x together ...

Further analysis of Vacc-4x phase IIb study shows a statistically significant reduction in viral load over placebo - Bionor Pharma reverses decision to put Vacc-4x on hold After further analyses ...

Oslo 13.08.2012 - Study of Vacc-4x Combined with Celgene`s Revlimid® (lenalidomide) in HIV Patients with Impaired Immune System Approved to Begin --Placebo-controlled, double-blind clinical study ...

The peptide-based therapeutic vaccine Vacc-4x appears to reduce viral load in patients with HIV who maintain viral suppression without antiretroviral therapy (ART) for 6 months.

After further analyses of the international, randomized, double-blind, placebo-controlled multi-center phase IIb study of Bionor Pharma's therapeutic HIV-vaccine candidate, Vacc-4x, the Company ...

Participants with anti-C5/gp41732-744 antibody levels below 4μg/ml who received Vacc-4x had a median viral load reduction of log 0.20 or 37% (p=0.019, n=27) compared to their median pre-ART viral ...

GLOBVAC Awards Bionor Pharma US$1.7 Million to Advance Research Towards an HIV Cure Using Vaccine Vacc-4x Award Represents Vital Step to Research Future Solutions for People Living With HIV OSLO, ...

Feb 24 (Reuters) - Bionor Pharma ASA : * Said on Tuesday third and final assay for measuring latent HIV reservoir size, the primary endpoint in the REDUC Part B trial, supports that the ...

• Bionor Pharma ASA, of Oslo, Norway, reported a statistically significant reduction in viral load of HIV virus at the end of its Phase IIb study testing its therapeutic HIV vaccine candidate, Vacc-4x ...

Bionor: final assay in REDUC trial supports Shock&Kill approach using Vacc-4x and romidepsin. By Reuters. February 24, 2016 6:35 AM UTC Updated February 24, 2016 Feb 24 (Reuters ...